Trial Profile
Study of CERC-301 for patients with severe major depressive disorder
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs Rislenemdaz (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 06 Oct 2016 New trial record
- 26 Sep 2016 According to Cerecor media release, the company received Fast Track Designation by the US FDA n 2013 for CERC-301, top-line data from this trial is expected in November 2016.